Annual Report · 10-K
Geron Corporation
GERNNASDAQEQUITYCurrent
Annual Report
Company context
meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.
Current securities
Historical securities (1)
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗